0.43p
+1.19%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Physiomics
Its shares trade on LSE under the ticker PYC.L. It has been listed since 20 December 2004. In the fiscal year to 30 June 2026, it reported revenue of £941,222 and a net loss of £697,034. At that date it held total assets of £788,551 and shareholders' equity of £523,977.
Physiomics Plc engages in the provision of outsourced systems and computational biology services to pharmaceutical companies. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2004-12-20. The firm is focused on the development of Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials; Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates in the drug discovery process, and Drug combinations database, for researchers and clinicians to access literature data on pre-clinical and clinical regimens and their effects. Its services include Target Validation, Mechanism of Action Studies, Lead Selection, Clinical Pharmacokinetic/Pharmacodynamics (PK/PD), EASYAP/Cardiac Toxicity Service, Virtual Tumour Preclinical and Virtual Tumour Clinical. The company offers a services and technology for predicting cardiac toxicity. The company also focuses on offering offer Model Based Drug Development (MBDD) services, which include Population PKPD analysis of clinical data and Back-translational analysis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 20 Dec 2004
- Employees
- 7
- Website
- physiomics-plc.com ↗
Leadership
Pay as last reported
- Dr. Jim MillenNon-Executive Chairman of the Board, since 2016£67,433
- Dr. Peter SargentChief Executive Officer, Executive Director, since 2023£78,746
- Mr. Anthony ClaydenCompany Secretary, Head of Finance
- Dr. Timothy CornIndependent Non-Executive Director£20,000
- Mr. Shalabh KumarIndependent Non-Executive Director£20,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Physiomics PLC has a strong expertise in mathematical modeling and simulations in the field of personalized medicine.
- The company's technology platform enables efficient and accurate prediction of patient response to various treatment options, offering cost and time savings.
- Physiomics PLC has established collaborations with renowned pharmaceutical companies, which enhances its credibility and market presence.
- The company's strong intellectual property portfolio gives it a competitive advantage and acts as a barrier to entry for competitors.
Weaknesses
- Physiomics PLC's success heavily depends on the adoption of personalized medicine approaches by the healthcare industry, which may be hindered by regulatory and reimbursement challenges.
- The company's limited financial resources may restrict its ability to fully capitalize on market opportunities and invest in research and development.
- Physiomics PLC operates in a highly competitive market, where larger and well-established companies may have greater resources and market reach.
Opportunities
- The increasing focus on personalized medicine and targeted therapies provides a significant growth opportunity for Physiomics PLC.
- The growing availability of patient data and advancements in technology open avenues for the company to further enhance its predictive capabilities.
- Physiomics PLC can explore partnerships with academic institutions and clinical research organizations to expand its data pool and validate its models.
- The global market for predictive personalized medicine is expected to grow at a rapid pace, offering ample opportunities for Physiomics PLC to expand its customer base.
Threats
- The evolving regulatory landscape and uncertainty surrounding reimbursement policies may pose challenges for Physiomics PLC's business model.
- The emergence of competing technologies and companies in the field of personalized medicine could threaten Physiomics PLC's market position.
- Economic downturns or funding constraints within the healthcare industry may impact customers' willingness to invest in predictive personalized medicine solutions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.